ESI-GROUP
Regulatory News:
ESI Group (ISIN Code: FR0004110310, Symbol: ESI) (Paris:ESI) , a global simulation and virtual prototyping software partner for the industry, will be present at the Farnborough International Airshow (18 and 22 July 2022). ESI Group will present an outline of aircraft Acoustics for both interior and exterior noise. Besides, The Group will illustrate how virtual reality solutions help power industry 4.0, showcasing and demonstrating its solution for human-centric virtual simulation and collaborative work with IC.IDO .
2 software solutions presented:
- ESI’s flagship Virtual Reality software IC.IDO for human-centric process validation and product integration: facilitating agile design processes, robust manufacturing, and safe maintenance operations.
- ESI’s vibro-acoustics software VA ONE for aircraft interiors and electric aircraft like eVTOL concepts: meeting interior noise level comfort and optimizing exterior noise impact in urban areas
Promising progress in the aircraft industry thanks to digitalization and virtual reality
Digitalization plays a major role in developing sustainable aviation, hydrogen planes, electric aircraft, urban mobility, eVTOLs... Virtual reality helps industries achieve sustainability goals, to secure “first time right”, reduce costs, time and go to market. Throughout the years, Virtual reality upgraded processes, allowing faster turnaround for foundries and composite parts manufacturers, lower scrap rates, manufacturability despite new geometries. Industrials have been able to achieve their desired vibro-acoustic performance and virtually pre-certified products. Besides, the need for physical try-outs and prototypes significantly decreased, paving the way to more efficient assembly steps, increased productivity and output, reduced maintenance costs, and decreased industrial risks for operators.
ESI Group has been operating in the aircraft industry for the last decades. ESI’s aerospace customers leverage the benefits of virtual reality solutions, helping them achieve their goal to producing clean, safe, and productive.
eVTOLS: ESI Group helps foster innovations – interior external noise and comfort
ESI has the mission to help aerospace companies in gearing their digital transformation, to be a partner they can trust to help foster innovations, such as the eVTOLS, that will change the landscape of urban mobility. ESI Group is already helping the pioneers of that segment achieve their product performance and safety targets while meeting stringent noise regulations, reducing noise impact in urban areas and meeting interior aircraft noise comfort levels. ESI Group’s VA One software solution help manufacturers to predict and resolve potential noise and vibration challenges in very early stages of their development process. Thus, meeting safety standards and their objectives for aircraft acoustics, and minimizing weight and controlling costs.
ESI Group’s software solutions for a clean, safe, and productive industry
1. Power systems manufacturer Rolls-Royce uses ESI casting simulation software ProCAST for Product-Process co-design and to collaborate more efficiently with their supply chain towards greater quality parts, avoiding late design changes and eliminating scrap rates in a more sustainable manner .
2. Saab Aerospace Systems relies on ESI composites manufacturing simulation software PAM-COMPOSITES to refine their injection strategies for the next generation aircraft doors , supporting the advanced manufacturing of ever lighter structures.
3. Latécoère counts on the advanced virtual reality capabilities provided by IC.IDO (1) , to connect manufacturing engineering teams from around the world on the same virtual platform to secure “First Time Right” production and to train operators remotely , cutting down on travel emissions, yet providing a “learning by doing” approach.
(1) ESI Group at the exhibition: France Pavillion. ESI Group will be part of the GIFAS (& “AsTech”) area in HALL 1 – Booth 13.60 Village ASTech
About ESI Group
Founded in 1973, ESI Group envisions a world where Industry commits to bold outcomes, addressing high-stakes concerns - environmental impact, safety & comfort for consumers and workers, adaptable and sustainable business models. ESI provides reliable and customized solutions anchored on predictive physics modeling and virtual prototyping expertise to allow industries to make the right decisions at the right time while managing their complexity. Acting principally in automotive & land transportation, aerospace, defense & naval and heavy industry, ESI is present in more than 20 countries, employs 1200 people around the world, and reported 2021 sales of €136.6 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris.
For further information, go to www.esi-group.com .
Follow ESI: LinkedIn | Facebook | Twitter | YouTube
View source version on businesswire.com: https://www.businesswire.com/news/home/20220717005031/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom